The management of erectile dysfunction in men with diabetes mellitus unresponsive to Phosphodiesterase type 5 inhibitors

Axel Alberto Cayetano‐Alcaraz,Tharu Tharakan,Runzhi Chen,Nikolaos Sofikitis,Suks Minhas

DOI: https://doi.org/10.1111/andr.13257

2022-08-17

Andrology

Abstract:Introduction : Erectile dysfunction (ED) is associated with diabetes mellitus with an estimated prevalence of 52.5% in the diabetic population. The first‐line therapy for ED are phosphodiesterase type 5 inhibitors (PDE5i), but data suggests that diabetic men may be less responsive than non‐diabetic men. Thus, other treatments, including intracavernosal injections, intraurethral prostaglandin, vacuum erection devices, and penile prosthetic surgery, should be considered in management of diabetic men with ED refractory to PDE5i. Furthermore, combination therapy of PDE5i and other oral treatments such as arginine or L‐carnitine may have synergistic effects resulting in better outcomes. In addition, there are novel therapies such as low‐intensity shockwave therapy and stem cell therapy which may also be effective targeted treatment modalities. Furthermore, studies suggest that ED can be improved by targeting concurrent comorbidities or metabolic diseases such as depression, hypertension, hypogonadism, and dyslipidaemia. We present an evidence‐based narrative review focussing on the management of ED in diabetic men who have not responded to PDE5i. Conclusions : Both clinicians and patients should be aware of the different management options in Diabetic patients who have responded to PDE5i. This article is protected by copyright. All rights reserved

andrology